Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 7, 2024.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Moderna Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Accounts payable 2.82 1.88 1.22 0.25 0.45
Provisions related to product sales 3.02 0.00 0.00 0.00 0.00
Compensation-related 1.33 0.73 0.51 1.30 1.73
Clinical trials 0.95 1.23 1.15 1.33 0.40
Manufacturing 0.91 1.55 0.92 0.73 0.37
Development operations 0.76 0.34 0.56 0.40 0.16
Other external goods and services 0.74 1.02 0.32 1.25 1.35
Royalties 0.66 0.79 0.98 0.00 0.00
Property, plant and equipment 0.51 0.02 0.00 0.00 0.00
Loss on future firm purchase commitments 0.43 1.04 0.00 0.00 0.00
Commercial 0.30 0.19 0.48 0.33 0.25
Raw materials 0.15 1.22 1.05 1.06 0.00
Accrued liabilities 9.76% 8.13% 5.97% 6.40% 4.26%
Deferred revenue 3.08 7.88 25.35 52.71 3.98
Income taxes payable 0.34 0.19 3.55 0.00 0.00
Financing lease liabilities, current 0.00 0.62 0.67 0.33 0.00
Operating lease liabilities, current 0.14 0.14 0.19 0.08 0.23
Other 0.22 0.20 0.06 0.05 0.09
Other current liabilities 0.36% 0.96% 0.91% 0.46% 0.32%
Current liabilities 16.36% 19.04% 37.00% 59.82% 9.00%
Deferred revenue, non-current 0.45 2.60 2.49 2.42 8.75
Operating lease liabilities, non-current 3.49 0.36 0.43 1.33 5.89
Financing lease liabilities, non-current 3.12 3.53 2.43 1.50 2.43
Other non-current liabilities 1.39 0.52 0.31 0.03 0.01
Non-current liabilities 8.45% 7.01% 5.66% 5.27% 17.08%
Total liabilities 24.81% 26.05% 42.66% 65.09% 26.09%
Preferred stock, $0.0001; no shares issued or outstanding 0.00 0.00 0.00 0.00 0.00
Common stock, par value $0.0001 0.00 0.00 0.00 0.00 0.00
Additional paid-in capital 2.01 4.54 17.07 65.45 167.95
Accumulated other comprehensive income (loss) -0.67 -1.43 -0.10 0.04 0.11
Retained earnings (accumulated deficit) 73.84 70.85 40.37 -30.58 -94.15
Stockholders’ equity 75.19% 73.95% 57.34% 34.91% 73.91%
Total liabilities and stockholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


Accounts payable
There is a noticeable increasing trend from 0.25% in 2020 to 2.82% in 2023, indicating a growing proportion of accounts payable relative to total liabilities and equity.
Provisions related to product sales
Data is only available for 2023, showing a significant percentage of 3.02%, which could imply newly recognized or accumulated product-related liabilities in that year.
Compensation-related liabilities
The percentage decreased from 1.73% in 2019 to 0.51% in 2021, followed by an increase to 1.33% in 2023, suggesting fluctuations in accrued compensation costs or related obligations.
Clinical trials
After a rise from 0.4% in 2019 to a peak of 1.33% in 2020, there is a gradual decline to 0.95% in 2023, indicating reduced relative liabilities associated with clinical trials over time.
Manufacturing
The manufacturing liabilities increased consistently from 0.37% in 2019 to 1.55% in 2022 before declining to 0.91% in 2023, reflecting possible expansion followed by a reduction in associated obligations.
Development operations
Percentages rose from 0.16% in 2019 to 0.56% in 2021 but decreased in 2022, then increased again to 0.76% in 2023, showing a somewhat variable trend in development-related liabilities.
Other external goods and services
This category dropped sharply from 1.35% in 2019 to 0.32% in 2021, rose again to 1.02% in 2022, then declined to 0.74% in 2023, indicating volatility in external service-related liabilities.
Royalties
Starting data from 2021 shows a decline from 0.98% to 0.66% in 2023, reflecting a decreasing proportion of royalty liabilities.
Property, plant and equipment
Values appear only beginning 2022 with a small increase from 0.02% to 0.51% in 2023, indicating a rise in liabilities or commitments related to fixed assets.
Loss on future firm purchase commitments
Recorded only from 2022 at 1.04%, decreasing to 0.43% in 2023, suggesting a reduction in estimated losses from future commitments.
Commercial
Shows fluctuations between 0.25% and 0.48% from 2019 to 2021, followed by lower values in 2022 and slight rebound in 2023, indicating relatively stable commercial liabilities with minor variation.
Raw materials
After appearing in 2020 at 1.06%, the figure remains around 1.05-1.22% through 2022, sharply dropping to 0.15% in 2023, signifying a large decrease in raw material-related liabilities.
Accrued liabilities
A steady increase from 4.26% in 2019 to a peak of 9.76% in 2023 demonstrates growing accrued obligations over the years.
Deferred revenue (current)
There is a dramatic rise in 2020 to 52.71%, followed by a decline each year to 3.08% in 2023, indicating a strong initial buildup of deferred revenue that reduced substantially over time.
Income taxes payable
Values initiate at 3.55% in 2021 and then fall to under 0.5% by 2023, suggesting a reduction in income tax liabilities.
Financing and operating lease liabilities (current and non-current)
Current financing lease liabilities showed small fluctuations without a clear trend. Operating leases decreased both in current and non-current categories from 2019 to 2022 but non-current operating leases surged in 2023 to 3.49%, possibly indicating lease restructuring or new lease agreements.
Other current and non-current liabilities
Current other liabilities rose modestly from 0.32% to 0.96% by 2022 before dropping to 0.36% in 2023. Non-current other liabilities increased steadily, reaching 1.39% in 2023, showing an upward trend in less defined or miscellaneous liabilities over time.
Current liabilities (total)
These peaked sharply at 59.82% in 2020, then consistently decreased to 16.36% in 2023, indicating a significant reduction in short-term obligations relative to total financing and equity.
Deferred revenue, non-current
Decreased notably from 8.75% in 2019 to 0.45% in 2023, showing diminishing long-term deferred revenue obligations.
Total non-current liabilities
Experienced a decline from 17.08% in 2019 to around 5-7% in the subsequent years, rising to 8.45% by 2023, indicating some growth in longer-term liabilities after an initial reduction.
Total liabilities
A notable spike in 2020 to 65.09% was followed by a continuous decline to 24.81% in 2023, showing a normalization or reduction in liabilities as a share of total financing over time.
Additional paid-in capital
Demonstrated a strong decline from 167.95% in 2019 to 2.01% in 2023, signifying a substantial contraction in capital contributions relative to total liabilities and equity.
Accumulated other comprehensive income (loss)
Fluctuated from a slight positive in 2019 to a negative value of -1.43% in 2022, with a slight recovery to -0.67% in 2023, indicating losses or unfavorable adjustments in accumulated comprehensive income over the period.
Retained earnings (accumulated deficit)
Shifted from a large deficit of -94.15% in 2019 to positive areas starting 2021, increasing to 73.84% by 2023, signaling a strong recovery in earnings retention and improved profitability or accumulated results.
Stockholders’ equity (total)
Experienced a reduction from 73.91% in 2019 to 34.91% in 2020, then steadily increased to 75.19% in 2023, indicating rebuilding or strengthening of the equity base over time.
Total liabilities and stockholders’ equity
This remained constant at 100% by definition, serving as the basis for all percentage comparisons.